191 related articles for article (PubMed ID: 37993930)
21. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
22. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
23. Base editing of the mutated TERT promoter inhibits liver tumor growth.
Zhao G; Ma Q; Yang H; Jiang H; Xu Q; Luo S; Meng Z; Liu J; Zhu L; Lin Q; Li M; Fang J; Ma L; Qiu W; Mao Z; Lu Z
Hepatology; 2024 Jun; 79(6):1310-1323. PubMed ID: 38016019
[TBL] [Abstract][Full Text] [Related]
24. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.
Xi L; Schmidt JC; Zaug AJ; Ascarrunz DR; Cech TR
Genome Biol; 2015 Nov; 16():231. PubMed ID: 26553065
[TBL] [Abstract][Full Text] [Related]
25. Allele-specific genome targeting in the development of precision medicine.
Wu J; Tang B; Tang Y
Theranostics; 2020; 10(7):3118-3137. PubMed ID: 32194858
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations.
Maryoung L; Yue Y; Young A; Newton CA; Barba C; van Oers NS; Wang RC; Garcia CK
J Clin Invest; 2017 Mar; 127(3):982-986. PubMed ID: 28192371
[TBL] [Abstract][Full Text] [Related]
27. Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.
Hirata M; Fujita K; Fujihara S; Mizuo T; Nakabayashi R; Kono T; Namima D; Fujita N; Yamana H; Kamada H; Tani J; Kobara H; Tsutsui K; Matsuda Y; Ono M; Masaki T
In Vivo; 2022; 36(1):94-102. PubMed ID: 34972704
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Lin L; Liu Y; Xu F; Huang J; Daugaard TF; Petersen TS; Hansen B; Ye L; Zhou Q; Fang F; Yang L; Li S; Fløe L; Jensen KT; Shrock E; Chen F; Yang H; Wang J; Liu X; Xu X; Bolund L; Nielsen AL; Luo Y
Gigascience; 2018 Mar; 7(3):1-19. PubMed ID: 29635374
[TBL] [Abstract][Full Text] [Related]
29. Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women.
Vinothkumar V; Arun K; Arunkumar G; Revathidevi S; Ramani R; Bhaskar LVKS; Murugan AK; Munirajan AK
Mol Clin Oncol; 2020 May; 12(5):485-494. PubMed ID: 32257207
[TBL] [Abstract][Full Text] [Related]
30. Efficient Targeted DNA Methylation with dCas9-Coupled DNMT3A-DNMT3L Methyltransferase.
Bashtrykov P; Rajaram N; Jeltsch A
Methods Mol Biol; 2023; 2577():177-188. PubMed ID: 36173573
[TBL] [Abstract][Full Text] [Related]
31. Hypomethylated CpG around the transcription start site enables TERT expression and HPV16 E6 regulates TERT methylation in cervical cancer cells.
Jiang J; Zhao LJ; Zhao C; Zhang G; Zhao Y; Li JR; Li XP; Wei LH
Gynecol Oncol; 2012 Mar; 124(3):534-41. PubMed ID: 22108635
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
33. Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease.
Christie KA; Robertson LJ; Conway C; Blighe K; DeDionisio LA; Chao-Shern C; Kowalczyk AM; Marshall J; Turnbull D; Nesbit MA; Moore CBT
Mol Ther; 2020 Aug; 28(8):1846-1857. PubMed ID: 32416058
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma.
Hirokawa T; Arimasu Y; Chiba T; Fujiwara M; Kamma H
Pathol Int; 2020 Apr; 70(4):217-223. PubMed ID: 31943527
[TBL] [Abstract][Full Text] [Related]
35. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.
Cárcano FM; Vidal DO; van Helvoort Lengert A; Neto CS; Queiroz L; Marques H; Baltazar F; da Silva Martinelli CM; Soares P; da Silva EC; Lopes LF; Reis RM
Tumour Biol; 2016 Apr; 37(4):4901-7. PubMed ID: 26526580
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
37. Concurrent genome and epigenome editing by CRISPR-mediated sequence replacement.
Alexander J; Findlay GM; Kircher M; Shendure J
BMC Biol; 2019 Nov; 17(1):90. PubMed ID: 31739790
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Simon M; Hosen I; Gousias K; Rachakonda S; Heidenreich B; Gessi M; Schramm J; Hemminki K; Waha A; Kumar R
Neuro Oncol; 2015 Jan; 17(1):45-52. PubMed ID: 25140036
[TBL] [Abstract][Full Text] [Related]
39. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
[TBL] [Abstract][Full Text] [Related]
40. Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Chiba K; Johnson JZ; Vogan JM; Wagner T; Boyle JM; Hockemeyer D
Elife; 2015 Jul; 4():. PubMed ID: 26194807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
